Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dow Development Labs Expands Petaluma Facilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dow Development Labs Expands Petaluma Facilities

CDMO specializes in topical products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Basin Street Properties, a Northern California real estate investor and developer, has signed a lease expansion for 11,053 square feet with

Dow Development Laboratories (DDL) is expanding their Petaluma, CA facility by 11,053 square feet. This addition doubles their total facility footprint to 22,698 square feet.

DDL is a contract development and manufacturing organization (CDMO) specializing in topical products. They opened their Petaluma facilities in 2014.

“Recent business success in product development has propelled us to outgrow the initial space and provided the rationale for our expansion,” said Debra Dow, president, DDL. “DDL specializes in the development of topical products such as creams, gels, solutions and ointments, most often for use in dermatology medical indications such as acne, psoriasis, and atopic dermatitis, as well as in ophthalmology, topical pain, women’s health and anti-infective therapy.”

DDL provides contract product development services to the pharmaceutical and biotech industry. Its clients range from start-ups to large multi-national companies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics